Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Directive 2010/84/EU | Statement: [Directive 2001/83/EC, amendedBy, Directive 2010/84/EU]

Target entity: Directive 2010/84/EU
Context triple: [Directive 2001/83/EC, amendedBy, Directive 2010/84/EU]

• A. Directive 2010/53/EU
  Directive 2010/53/EU is a European Union law that sets common standards for the quality and safety of human organs intended for transplantation across EU member states.
• B. Directive 2006/86/EC
  Directive 2006/86/EC is a European Union legal act that sets detailed technical requirements for the traceability, notification of serious adverse reactions and events, and quality and safety standards for human tissues and cells used in medical treatments.
• C. Directive 2014/65/EU
  Directive 2014/65/EU is a key European Union legislative act that overhauls and strengthens the regulatory framework for investment services and financial markets, commonly known as MiFID II.
• D. Directive 2001/83/EC
  Directive 2001/83/EC is a key European Union law that sets the framework for the authorization, manufacture, distribution, and pharmacovigilance of medicinal products for human use across EU member states.
• E. Directive 2013/37/EU
  Directive 2013/37/EU is a European Union law that updated and expanded the rules on the re-use of public sector information to promote transparency, innovation, and economic activity across the EU.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Directive 2010/84/EU
Target entity description: Directive 2010/84/EU is a European Union legislative act that significantly strengthened and modernized the EU pharmacovigilance system to improve the monitoring and safety of medicinal products for human use.

• A. Directive 2010/53/EU
  Directive 2010/53/EU is a European Union law that sets common standards for the quality and safety of human organs intended for transplantation across EU member states.
• B. Directive 2006/86/EC
  Directive 2006/86/EC is a European Union legal act that sets detailed technical requirements for the traceability, notification of serious adverse reactions and events, and quality and safety standards for human tissues and cells used in medical treatments.
• C. Directive 2014/65/EU
  Directive 2014/65/EU is a key European Union legislative act that overhauls and strengthens the regulatory framework for investment services and financial markets, commonly known as MiFID II.
• D. Directive 2001/83/EC
  Directive 2001/83/EC is a key European Union law that sets the framework for the authorization, manufacture, distribution, and pharmacovigilance of medicinal products for human use across EU member states.
• E. Directive 2013/37/EU
  Directive 2013/37/EU is a European Union law that updated and expanded the rules on the re-use of public sector information to promote transparency, innovation, and economic activity across the EU.
• F. None of above. chosen